The AIS Cancer Center | Clinical Trials

Title Disease Type Protocol Status Phase Trial Type
A Phase 1 Study of Pembrolizumab (MK-3475) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors Solid Tumor Active I INTERVENTION
A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia Leukemia Active I INTERVENTION
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Male Reproductive System Cancer Active I/II INTERVENTION
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma Bone Cancer Temporarily Closed to Accrual II INTERVENTION
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients with HIV Infection AIDS-related Malignancy and Condition;Solid Tumor Active I INTERVENTION
Phase I/Ib Trial of ATR Inhibitor BAY 1895344 in Combination with FOLFIRI in GI Malignancies with a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers Gastrointestinal Cancer Active I INTERVENTION
A Randomized Phase 2 Study of Atezolizumab with or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM) Soft Tissue Cancer/Sarcoma Active II INTERVENTION
A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT Carcinoma Miscellaneous and Metastatic Cancer Active I/II INTERVENTION
A Phase 1 Study of Nivolumab in Combination with ASTX727 in B-cell Lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Lymphoma Active I INTERVENTION
Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer AIDS-related Malignancy and Condition;Female Reproductive System Cancer Active I INTERVENTION
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors Solid Tumor Active I INTERVENTION
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer Gastrointestinal Cancer Active III INTERVENTION
Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors Endocrine Cancer Active II INTERVENTION
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease Leukemia Active II INTERVENTION
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas Lymphoma Active II INTERVENTION
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations CNS Cancer (Primary tumor) Active II SCREENING, INTERVENTION
A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma Skin Cancer Active II INTERVENTION
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice) Lung, Mediastinal, and Pleural Cancer Active II INTERVENTION
BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation N/A Active III INTERVENTION
Blinded Reference Set For Multicancer Early Detection Blood Tests Miscellaneous and Metastatic Cancer Active Other OTHER
Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma AIDS-related Malignancy and Condition Temporarily Closed to Accrual I SCREENING, INTERVENTION
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Solid Tumor Active Other OTHER
EA1181 (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer) Breast Cancer Active II INTERVENTION
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation Gastrointestinal Cancer Active II INTERVENTION
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis Lung, Mediastinal, and Pleural Cancer Active III INTERVENTION
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma Skin Cancer Active II/III INTERVENTION
InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) Male Reproductive System Cancer Active III INTERVENTION
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) Myeloma Active III INTERVENTION
A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery Breast Cancer Temporarily Closed to Accrual II INTERVENTION
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) Kidney Cancer Active II INTERVENTION
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin Solid Tumor Active I INTERVENTION
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma CNS Cancer (Primary tumor) Active I INTERVENTION
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients with Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma Bone Cancer;CNS Cancer (Primary tumor);Lymphoma;Solid Tumor Temporarily Closed to Accrual I/II INTERVENTION
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) Gastrointestinal Cancer Active III INTERVENTION
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III Breast Cancer Active III SCREENING, INTERVENTION
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease Leukemia Active II INTERVENTION
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC Lung, Mediastinal, and Pleural Cancer Active III INTERVENTION
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status Lung, Mediastinal, and Pleural Cancer Active II INTERVENTION
A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy Urothelial/ Bladder Cancer Active III INTERVENTION
A Phase II Randomized Study of Ibrutinib and Rituximab with or Without Venetoclax in Previously Untreated Waldenstr÷m's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) Lymphoma Temporarily Closed to Accrual II INTERVENTION
Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) Endocrine Cancer Active II/III INTERVENTION
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study N/A Active Other OTHER
A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma Myeloma Active I INTERVENTION
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Head and Neck Cancer Active I INTERVENTION
A Phase I Study of Anetumab Ravtansine in Combination with Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma Gastrointestinal Cancer Active I/II SCREENING, INTERVENTION
Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers Gastrointestinal Cancer;Skin Cancer;Solid Tumor Temporarily Closed to Accrual I INTERVENTION
A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer Male Reproductive System Cancer Active II INTERVENTION
A Phase I Trial of MLN0128 (Sapanisertib) and Telaglenastat (CB-839) HCL in Advanced NSCLC Patients Lung, Mediastinal, and Pleural Cancer Temporarily Closed to Accrual I INTERVENTION
A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) Leukemia;Lymphoma Active I INTERVENTION
A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) with Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer Gastrointestinal Cancer Temporarily Closed to Accrual I INTERVENTION
A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer Female Reproductive System Cancer Temporarily Closed to Accrual I INTERVENTION
A Phase 2 Study of Ipatasertib in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Head and Neck Cancer Active II INTERVENTION
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib Breast Cancer Active III INTERVENTION
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS) Gastrointestinal Cancer Active III INTERVENTION
A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma Endocrine Cancer Active II INTERVENTION
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent WHO Grade 4 Glioma CNS Cancer (Primary tumor) Active II SCREENING, INTERVENTION
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse Leukemia Active II INTERVENTION
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma Bone Cancer Active III INTERVENTION
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups Kidney Cancer Active II INTERVENTION
A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) plus Memantine for 5-15 Brain Metastases Miscellaneous and Metastatic Cancer Active III INTERVENTION
Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer Breast Cancer Active III SCREENING, INTERVENTION
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein Lung, Mediastinal, and Pleural Cancer Active III INTERVENTION
A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Na´ve Metastatic Pancreatic Cancer (GIANT) Gastrointestinal Cancer Active II INTERVENTION
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE) Male Reproductive System Cancer Active III SCREENING, INTERVENTION
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation Myeloma Active III SCREENING, INTERVENTION
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas CNS Cancer (Primary tumor) Active II SCREENING, INTERVENTION
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE) Male Reproductive System Cancer Active III INTERVENTION
Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined with Dinutuximab in Children and Young Adults with Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma Bone Cancer;Nervous System Cancer (CNS-excluded) Active I INTERVENTION
A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study) Lung, Mediastinal, and Pleural Cancer Active II/III INTERVENTION
Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention Into Care (MiChoice) Breast Cancer Active Other INTERVENTION
A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT) Miscellaneous and Metastatic Cancer;Solid Tumor Active Other INTERVENTION
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC) Lung, Mediastinal, and Pleural Cancer Active II SCREENING, INTERVENTION
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations Gastrointestinal Cancer Active II INTERVENTION
Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS) Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Solid Tumor Active III INTERVENTION
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors Female Reproductive System Cancer;Lymphoma;Skin Cancer Active II INTERVENTION
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE) Male Reproductive System Cancer Active I/II INTERVENTION
A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option Urothelial/ Bladder Cancer Active II INTERVENTION
A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients with CCNE1 Amplification Solid Tumor Temporarily Closed to Accrual II INTERVENTION
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Gastrointestinal Cancer;Solid Tumor Active I/II INTERVENTION
Cancer Moonshot Biobank Research Protocol Gastrointestinal Cancer;Leukemia;Lung, Mediastinal, and Pleural Cancer;Male Reproductive System Cancer;Myeloma;Skin Cancer Active Other OTHER
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) with Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC) Female Reproductive System Cancer Active I INTERVENTION
Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-Expressing Advanced Solid Tumors Solid Tumor Active I INTERVENTION
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma Bone Cancer;Soft Tissue Cancer/Sarcoma Active II INTERVENTION
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA) Endocrine Cancer;Gastrointestinal Cancer;Lung, Mediastinal, and Pleural Cancer;Solid Tumor Active I INTERVENTION
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination with Cisplatin and with Cisplatin Plus Gemcitabine in Advanced Solid Tumors with an Emphasis on Urothelial Carcinoma Solid Tumor;Urothelial/ Bladder Cancer Active I INTERVENTION
Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients with Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-Deficient Gastrointestinal Stromal Tumor (GIST) Soft Tissue Cancer/Sarcoma Active II INTERVENTION
Phase Ib/II Study of EPA-Based EphA2 Targeted Therapy for Patients with Metastatic Triple-Negative Inflammatory Breast Cancer Breast Cancer Active I/II INTERVENTION
Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations Urothelial/ Bladder Cancer Active I INTERVENTION
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) Endocrine Cancer Active III INTERVENTION
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Germ Cell Cancer;Kidney Cancer;Male Reproductive System Cancer;Miscellaneous and Metastatic Cancer;Urothelial/ Bladder Cancer Active II INTERVENTION
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy Leukemia Temporarily Closed to Accrual II/III SCREENING, INTERVENTION
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype Lymphoma Active III SCREENING, INTERVENTION
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC) Skin Cancer Active II INTERVENTION
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor CNS Cancer (Primary tumor) Active II INTERVENTION
Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm AIDS-related Malignancy and Condition;Gastrointestinal Cancer;Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Lung, Mediastinal, and Pleural Cancer;Lymphoma;Skin Cancer;Solid Tumor Active I INTERVENTION
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) Gastrointestinal Cancer Active II SCREENING, INTERVENTION
Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial Gastrointestinal Cancer Active II/III INTERVENTION
Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a (and Selected T4b) Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC) Head and Neck Cancer Active II INTERVENTION
STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial Skin Cancer Active III INTERVENTION
Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study Skin Cancer Active II INTERVENTION
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma CNS Cancer (Primary tumor) Active II INTERVENTION
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) Breast Cancer Active III SCREENING, INTERVENTION
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying treatment for NOde positive prostate cancer by VArying the hormonal ThErapy Male Reproductive System Cancer Active III INTERVENTION
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Female Reproductive System Cancer Active III INTERVENTION
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Female Reproductive System Cancer Active III INTERVENTION
Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Head and Neck Cancer Active II/III INTERVENTION
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC Lung, Mediastinal, and Pleural Cancer Active III INTERVENTION
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma Gastrointestinal Cancer Active II INTERVENTION
Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma Skin Cancer Active III INTERVENTION
A Phase 1B Study of KRT-232 (AMG-232) in Combination with Decitabine in Acute Myeloid Leukemia Leukemia Temporarily Closed to Accrual I INTERVENTION
A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination with Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma Lymphoma Temporarily Closed to Accrual I INTERVENTION
A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors with DNA-Repair Defects Endocrine Cancer;Germ Cell Cancer;Kidney Cancer;Male Reproductive System Cancer;Urothelial/ Bladder Cancer Active II SCREENING, INTERVENTION
Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients with Metastatic Triple Negative Breast Cancer Breast Cancer Active II INTERVENTION
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970, Berzosertib) Vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer Endocrine Cancer;Lung, Mediastinal, and Pleural Cancer Temporarily Closed to Accrual II INTERVENTION
A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination with Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine-Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA) Breast Cancer Active I/II INTERVENTION
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy Leukemia Active II INTERVENTION
A Phase I Study of DS-8201a in Combination with Olaparib in HER2-Expressing Malignancies Female Reproductive System Cancer;Solid Tumor Active I INTERVENTION
A Phase 1/2 Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma Gastrointestinal Cancer Temporarily Closed to Accrual I/II INTERVENTION
A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination with Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma Lymphoma Temporarily Closed to Accrual I/II INTERVENTION
Phase 1 Trial of Gemcitabine Combined with the BAY 1895344 ATR Inhibitor with Expansion Cohorts in Advanced Pancreatic and Ovarian Cancer Female Reproductive System Cancer;Gastrointestinal Cancer;Solid Tumor Active I INTERVENTION
Phase I Trial of BAY 1895344 ATR Inhibitor Combined with Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma Head and Neck Cancer Active I INTERVENTION
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) with or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers Gastrointestinal Cancer Temporarily Closed to Accrual II INTERVENTION
Phase 2 Trial of the Combination of the BET inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET) Solid Tumor Active II INTERVENTION
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI) Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Solid Tumor Active Other OTHER
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair Gastrointestinal Cancer Active III INTERVENTION
Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART) Urothelial/ Bladder Cancer Active II INTERVENTION
Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or Without Immunotherapy for Peritoneal Mesothelioma Lung, Mediastinal, and Pleural Cancer Active II INTERVENTION
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions Miscellaneous and Metastatic Cancer Active III INTERVENTION
Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer Patients Undergoing Post-Mastectomy Radiation Therapy: A Randomized Phase III Clinical Trial Breast Cancer Active III INTERVENTION
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS) Soft Tissue Cancer/Sarcoma Active III INTERVENTION
Phase 1 Study of NT-I7 (rhIL-7-hyFc) for the Treatment of Kaposi Sarcoma in Patients with or Without Infection with HIV AIDS-related Malignancy and Condition Active I INTERVENTION
Phase II Randomized Trial of Radiotherapy with or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing Head and Neck Cancer Active II INTERVENTION
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers Head and Neck Cancer Active II/III INTERVENTION
A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases From Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D) Skin Cancer Active II INTERVENTION
Phase II Study of Bladder-SparIng ChemoradiatioN with Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE) Urothelial/ Bladder Cancer Active II INTERVENTION
Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM) Myeloma Active III SCREENING, INTERVENTION
Molecular Analysis for Therapy Choice (MATCH) Lymphoma;Myeloma;Solid Tumor Active II SCREENING, INTERVENTION
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) Lung, Mediastinal, and Pleural Cancer Active Other SCREENING
The National Myelodysplastic Syndromes (MDS) Study Leukemia Active Other OTHER
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk] Female Reproductive System Cancer Active Other INTERVENTION
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel Male Reproductive System Cancer Active II/III INTERVENTION
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women with Recurrent or Persistent Endometrial Cancer Female Reproductive System Cancer Active II INTERVENTION
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab Female Reproductive System Cancer Active II INTERVENTION
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) Head and Neck Cancer Active II/III SCREENING, INTERVENTION
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations CNS Cancer (Primary tumor) Active I INTERVENTION
A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma CNS Cancer (Primary tumor) Active I INTERVENTION
A Randomized Phase III Double-Blind Clinical Trial Evaluating The Effect Of Immune-Enhancing Nutrition On Radical Cystectomy Outcomes (SIMmune) Urothelial/ Bladder Cancer Temporarily Closed to Accrual III INTERVENTION
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Solid Tumor Active II INTERVENTION
A Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma Lung, Mediastinal, and Pleural Cancer Active II INTERVENTION
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer Breast Cancer Active Other SCREENING, INTERVENTION
Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) Myeloma Active III INTERVENTION
Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer Urothelial/ Bladder Cancer Active III INTERVENTION
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study Leukemia;Lymphoma Active III INTERVENTION
NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer Lung, Mediastinal, and Pleural Cancer Active II INTERVENTION
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Solid Tumor Active Other INTERVENTION
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Solid Tumor Active I INTERVENTION
A Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients with Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia Leukemia Active I INTERVENTION
A Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO) Female Reproductive System Cancer;Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Kidney Cancer;Lung, Mediastinal, and Pleural Cancer;Lymphoma;Skin Cancer;Solid Tumor;Urothelial/ Bladder Cancer Active I INTERVENTION
A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients with Advanced Solid Tumors Solid Tumor Active I/II INTERVENTION
The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Leukemia Active II SCREENING, INTERVENTION
Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor Therapy Skin Cancer Active I/II INTERVENTION
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia Leukemia Active II INTERVENTION
Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer Breast Cancer Active II INTERVENTION
A Phase I Study with an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and SÚzary Syndrome (SS) Lymphoma Active I INTERVENTION
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response Breast Cancer;Female Reproductive System Cancer;Gastrointestinal Cancer;Male Reproductive System Cancer;Solid Tumor Active II INTERVENTION
A Phase 1 Study of IPdR in Combination with Capecitabine and Radiotherapy in Rectal Cancer Gastrointestinal Cancer Active I INTERVENTION
Randomized Phase 2 Study of CPX-351 + Pomalidomide Versus CPX-351 in Newly Diagnosed AML with MDS-Related Changes Leukemia Active II INTERVENTION
A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer Breast Cancer;Solid Tumor Active I INTERVENTION
A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer Kidney Cancer Temporarily Closed to Accrual II SCREENING, INTERVENTION
Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas Gastrointestinal Cancer;Lymphoma;Solid Tumor Active I/II INTERVENTION
Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors Endocrine Cancer Active II INTERVENTION
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas CNS Cancer (Primary tumor) Active II SCREENING, INTERVENTION
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO) Lung, Mediastinal, and Pleural Cancer Active III INTERVENTION
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer Lung, Mediastinal, and Pleural Cancer Active II/III INTERVENTION
Tomosynthesis Mammographic Imaging Screening Trial (TMIST) Breast Cancer Active III INTERVENTION
FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE Breast Cancer Active II INTERVENTION
A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma Gastrointestinal Cancer Temporarily Closed to Accrual II INTERVENTION
A Randomized Phase II Trial Evaluating Chemotherapy vs Chemotherapy Plus Bevacizumab and Atezolizumab in Advanced Combined Hepatocellular Carcinoma-Cholangiocarcinoma Gastrointestinal Cancer Active II INTERVENTION
Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR Lung, Mediastinal, and Pleural Cancer Temporarily Closed to Accrual II INTERVENTION
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS with Brain Metastasis Velocity >/= 4 Brain Metastases/Year Miscellaneous and Metastatic Cancer Active III INTERVENTION
A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma CNS Cancer (Primary tumor) Active III SCREENING, INTERVENTION
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer Gastrointestinal Cancer Active III INTERVENTION
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) Gastrointestinal Cancer Active II/III INTERVENTION
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer Female Reproductive System Cancer Active III INTERVENTION
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma Female Reproductive System Cancer Temporarily Closed to Accrual II INTERVENTION
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin Head and Neck Cancer Temporarily Closed to Accrual II/III SCREENING, INTERVENTION
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer Breast Cancer Active II INTERVENTION
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) Lung, Mediastinal, and Pleural Cancer Active III INTERVENTION
A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases Skin Cancer Active II INTERVENTION
Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP TRIAL Urothelial/ Bladder Cancer Active II INTERVENTION
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors CNS Cancer (Primary tumor);Gastrointestinal Cancer;Solid Tumor Active II INTERVENTION
A Phase 2 Single-Arm Study of M6620 in Combination with Irinotecan in Patients with Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer Gastrointestinal Cancer Active II INTERVENTION
DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination with Chemotherapy in Patients with Advanced Solid Tumors Solid Tumor Active II INTERVENTION
Phase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial) Gastrointestinal Cancer;Solid Tumor Active I INTERVENTION
A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple Negative Breast Cancer Breast Cancer Temporarily Closed to Accrual I/II INTERVENTION
A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Endocrine Cancer Active I SCREENING, INTERVENTION
Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 with PD-1 Inhibitor, Nivolumab with or Without CTLA-4 Inhibitor, Ipilimumab in Solid Tumors Female Reproductive System Cancer;Solid Tumor Active I INTERVENTION
Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer Lung, Mediastinal, and Pleural Cancer Active I INTERVENTION
A Phase 1b Trial of M3814 (Peposertib) in Combination with Lutetium 177 Dotatate for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Endocrine Cancer Active I INTERVENTION
Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination with Neratinib in Solid Tumors with HER2 Alterations Solid Tumor Active I INTERVENTION
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations Urothelial/ Bladder Cancer Active II INTERVENTION
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE] Kidney Cancer Active III INTERVENTION
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCal) Kidney Cancer Active II INTERVENTION
Genomically-Guided Treatment Trial in Brain Metastases Miscellaneous and Metastatic Cancer Active II SCREENING, INTERVENTION
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions Breast Cancer Active III INTERVENTION
Improving Patient-Centered Communication in Breast Cancer: A RCT of a Shared Decision Engagement System (SHARES) Breast Cancer Active Other INTERVENTION
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Lymphoma Active III INTERVENTION
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) Soft Tissue Cancer/Sarcoma Temporarily Closed to Accrual III INTERVENTION
A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma Lymphoma Active I/II INTERVENTION
A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Na´ve Metastatic Anal Cancer Patients Gastrointestinal Cancer Active III INTERVENTION
A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA) Gastrointestinal Cancer Active III INTERVENTION
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC Head and Neck Cancer Active II/III INTERVENTION
A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features Head and Neck Cancer Active II INTERVENTION
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission Lymphoma Active III INTERVENTION
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <= 70 Years Old with Untreated Mantle Cell Lymphoma Lymphoma Active II INTERVENTION
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC Lung, Mediastinal, and Pleural Cancer Active III INTERVENTION
The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma with Elevated LDH Skin Cancer Active II INTERVENTION
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) Skin Cancer Active II INTERVENTION
A Phase II/III Trial of MED14736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy Urothelial/ Bladder Cancer Active II/III INTERVENTION
A Phase IB/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia Leukemia;Lymphoma Temporarily Closed to Accrual I/II INTERVENTION
Implementing a Virtual Tobacco Treatment in Community Oncology Practices: "Smoke Free Support Study 2.0" Miscellaneous and Metastatic Cancer Active II INTERVENTION
N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma CNS Cancer (Primary tumor) Active III SCREENING, INTERVENTION
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma CNS Cancer (Primary tumor) Temporarily Closed to Accrual II INTERVENTION
Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (with Initial Phase I) Male Reproductive System Cancer Temporarily Closed to Accrual I/II INTERVENTION
A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy with or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean) Male Reproductive System Cancer Active II INTERVENTION
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma Female Reproductive System Cancer Active II/III INTERVENTION
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer Head and Neck Cancer Active II/III INTERVENTION
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer Head and Neck Cancer Active II/III SCREENING, INTERVENTION
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial Lung, Mediastinal, and Pleural Cancer Temporarily Closed to Accrual II/III INTERVENTION
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab Lung, Mediastinal, and Pleural Cancer Active II/III INTERVENTION
A Phase 1/ 2 Study of BAY 1895344 (elimusertib, NSC#810486) in Pediatric Patients with Relapsed or Refractory Solid Tumors Bone Cancer;Lymphoma;Soft Tissue Cancer/Sarcoma;Solid Tumor Active I/II INTERVENTION
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck Head and Neck Cancer Active II/III SCREENING, INTERVENTION
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma Lymphoma Active III INTERVENTION
A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study) Lung, Mediastinal, and Pleural Cancer Active II INTERVENTION
A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL) Leukemia;Lymphoma Active I/II INTERVENTION
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors Endocrine Cancer Active II INTERVENTION
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma Soft Tissue Cancer/Sarcoma Active II SCREENING, INTERVENTION
A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer Lung, Mediastinal, and Pleural Cancer Active II INTERVENTION
A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients with Advanced Solid Tumors Solid Tumor Active I INTERVENTION
A Phase 1b Study of Berzosertib in Combination with Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer Breast Cancer Active I INTERVENTION
A Phase IB and Randomized Open-Label Phase II Study of Berzosertib (M6620, VX-970) in Combination with Carboplatin/Gemcitabine/Pembrolizumab in Patients with Chemotherapy-Na´ve Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology Lung, Mediastinal, and Pleural Cancer Active I/II INTERVENTION
A Phase 0 Window-of-Opportunity Pharmacodynamic Trial of Triapine (NSC# 663249) in Uterine Corpus Serous Adenocarcinoma Female Reproductive System Cancer Active 0 INTERVENTION
Clinical Evaluation of ASTX727 in Combination with Venetoclax All-Oral Therapy vs Standard of Care Cytarabine and Anthracycline Induction Chemotherapy for Younger FLT3WT Patients with ELN High- Risk Acute Myeloid Leukemia Leukemia Active I/II INTERVENTION
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and Temozolomide Solid Tumor Active II INTERVENTION
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial Urothelial/ Bladder Cancer Active III INTERVENTION
A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM Male Reproductive System Cancer Active II INTERVENTION
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas Lymphoma Temporarily Closed to Accrual II/III INTERVENTION
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease Miscellaneous and Metastatic Cancer Active III INTERVENTION
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Lung, Mediastinal, and Pleural Cancer Active Other SCREENING, OTHER
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events Miscellaneous and Metastatic Cancer Active Other INTERVENTION
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia Miscellaneous and Metastatic Cancer Active III INTERVENTION
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Urothelial/ Bladder Cancer Active II INTERVENTION
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma Gastrointestinal Cancer Active II/III INTERVENTION
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs Gastrointestinal Cancer Active II INTERVENTION
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC Lung, Mediastinal, and Pleural Cancer Active II INTERVENTION
Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer Male Reproductive System Cancer Active II INTERVENTION
BLAST MRD CML 1 Trial: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD Leukemia Active II SCREENING, INTERVENTION
Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis Immune Disorder (excluding AIDS and malignancy) Active II INTERVENTION
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma CNS Cancer (Primary tumor) Temporarily Closed to Accrual II/III SCREENING, INTERVENTION
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) Gastrointestinal Cancer Active II/III INTERVENTION
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial Lung, Mediastinal, and Pleural Cancer Active II/III INTERVENTION
GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor Exposure Bone Cancer;Nervous System Cancer (CNS-excluded) Active I INTERVENTION
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer Male Reproductive System Cancer Active III INTERVENTION
A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY) Lung, Mediastinal, and Pleural Cancer Active II INTERVENTION
Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial) Kidney Cancer Active III INTERVENTION
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases Breast Cancer Active II INTERVENTION
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy AIDS-related Malignancy and Condition;Bone Cancer;Breast Cancer;CNS Cancer (Primary tumor);Endocrine Cancer;Eye Cancer;Female Reproductive System Cancer;Gastrointestinal Cancer;Germ Cell Cancer;Head and Neck Cancer;Kidney Cancer;Lung, Mediastinal, and Pleural Cancer;Male Reproductive System Cancer;Miscellaneous and Metastatic Cancer;Nervous System Cancer (CNS-excluded);Skin Cancer;Soft Tissue Cancer/Sarcoma;Solid Tumor;Urothelial/ Bladder Cancer Active Other INTERVENTION
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma Soft Tissue Cancer/Sarcoma Active II INTERVENTION
A Pilot Study of Tazemetostat and Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma Urothelial/ Bladder Cancer Active I/II INTERVENTION
A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma CNS Cancer (Primary tumor) Active I/II INTERVENTION
A Phase Ib Study of Osimertinib (AZD9291) and Telaglenastat (CB-839) HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer Lung, Mediastinal, and Pleural Cancer Active I/II INTERVENTION
A Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) Mutant Solid Tumors Gastrointestinal Cancer;Solid Tumor Active II INTERVENTION
A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Leukemia Active I INTERVENTION
Phase I Sequential Trial of Agents Against DNA Repair (STAR) Solid Tumor Temporarily Closed to Accrual I INTERVENTION
A Phase 1b Study with Expansion Cohort of Escalating Doses of KRT-232 (AMG 232) Administered in Combination with Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed Acute Myelogenous Leukemia (AML) Leukemia Active I INTERVENTION
A Phase 1/1a Study of Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis Immune Disorder (excluding AIDS and malignancy) Active I INTERVENTION
Phase I/Ib Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer Head and Neck Cancer Active I INTERVENTION
A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors Miscellaneous and Metastatic Cancer;Solid Tumor Temporarily Closed to Accrual I INTERVENTION
A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer Lung, Mediastinal, and Pleural Cancer Active II INTERVENTION
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors Female Reproductive System Cancer;Gastrointestinal Cancer;Kidney Cancer;Skin Cancer;Soft Tissue Cancer/Sarcoma;Solid Tumor Active I INTERVENTION
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors CNS Cancer (Primary tumor);Germ Cell Cancer Active III INTERVENTION
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Urothelial/ Bladder Cancer Active II INTERVENTION
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer Male Reproductive System Cancer Active III INTERVENTION
MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer Urothelial/ Bladder Cancer Active III INTERVENTION
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL Leukemia Temporarily Closed to Accrual III INTERVENTION
A Multicenter Phase II Trial of Paclitaxel with and Without Nivolumab in Taxane Na´ve, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma Soft Tissue Cancer/Sarcoma Active II INTERVENTION
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study Gastrointestinal Cancer Active II/III INTERVENTION
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin versus Placebo for Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy Male Reproductive System Cancer Active II INTERVENTION
Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg) Miscellaneous and Metastatic Cancer Active Other INTERVENTION
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) CNS Cancer (Primary tumor) Active I/II SCREENING, INTERVENTION
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors Germ Cell Cancer;Miscellaneous and Metastatic Cancer Active III INTERVENTION
A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors Germ Cell Cancer Active III INTERVENTION
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma Gastrointestinal Cancer Active II INTERVENTION
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Lung, Mediastinal, and Pleural Cancer Active III INTERVENTION
A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers Male Reproductive System Cancer Active II SCREENING, INTERVENTION
Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE) Male Reproductive System Cancer Active III INTERVENTION
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults Leukemia Active III SCREENING, INTERVENTION
A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL) Leukemia Active II INTERVENTION
COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation Breast Cancer Active III OTHER
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials Bone Cancer;Breast Cancer;CNS Cancer (Primary tumor);Endocrine Cancer;Female Reproductive System Cancer;Gastrointestinal Cancer;Germ Cell Cancer;Leukemia;Lymphoma;Miscellaneous and Metastatic Cancer;Skin Cancer;Soft Tissue Cancer/Sarcoma Active Pilot OTHER
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma CNS Cancer (Primary tumor) Active III SCREENING, INTERVENTION
A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases Miscellaneous and Metastatic Cancer Active III INTERVENTION
FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps) Gastrointestinal Cancer Active III INTERVENTION
Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer Miscellaneous and Metastatic Cancer Active III INTERVENTION
A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma Gastrointestinal Cancer Active III INTERVENTION
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer Gastrointestinal Cancer Active III INTERVENTION
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*) Male Reproductive System Cancer Active III INTERVENTION
Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy with or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) For Malignant Pleural Mesothelioma (MPM) Lung, Mediastinal, and Pleural Cancer Active III INTERVENTION
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma Lymphoma Temporarily Closed to Accrual II INTERVENTION
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors Solid Tumor Active III INTERVENTION
A Prospective Observational Cohort Study to Assess miRNA 371 For Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors Germ Cell Cancer Active Other INTERVENTION
A Phase II/III Randomized Study of R-MiniCHOP with or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC AND BCL2 and/or BCL6 Rearrangements Lymphoma Active II/III INTERVENTION
Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer Gastrointestinal Cancer Active II INTERVENTION
Women Informed to Screen Depending on Measures of Risk (Wisdom Study) Breast Cancer Active Other SCREENING
Metastatic Breast Cancer Project Metastatic Breast Cancer Active Other SCREENING
Metastatic Prostate Cancer Project Metastatic Prostate Cancer Active Other SCREENING
Esophageal and Stomach Cancer Project Esophageal and Stomach Cancer Active Other SCREENING
Brain Tumor Project Primary Brain Tumor Active Other SCREENING
Angiosarcoma Project Angiosarcoma Active Other SCREENING
Inherited Cancer Registry - Hereditary Cancers Inherited Cancer - Genetics Inherited Cancer - Genetics Active Other SCREENING
BESPOKE Study of ctDNA Guided Immunotherapy (BESPOKE IO) Colorectal Cancer, Melanoma, Non-small Cell Lung Cancer Active Other OBSERVATIONAL